EN PL
 
EN PL
Current issue
Archive
Online first
About the Journal
Instructions for authors
Books and Events
1/2010 vol. 48
Get citation
SHORT COMMUNICATION
Prevention of tuberculosis in patients treated with tumour necrosis factor antagonists
Maria Korzeniewska-Koseła
 
 
 
More details
Hide details
 
Online publication date: 2010-04-09
 
 
Reumatologia 2010;48(1):4-13
 
Article (PDF)
References (55)
 
KEYWORDS
TNF antagonists
tuberculosis
latent tuberculosis infection
chemoprophylaxis
 
ABSTRACT
Tumour necrosis factor inhibition increases the risk of tuberculosis. Active tuberculosis should be excluded and screening for latent tuberculosis infection should be done before commencement of treatment with tumour necrosis factor antagonists. Chest radiography and interferon-γ-release assay (IGRA) should be performed; medical history to screen for TB risk factors should be taken. IGRA use will help to reduce over-use and under-use of preventive treatment in candidates for TNF antagonist therapy. If a patient is diagnosed with latent TB infection, chemopreventive treatment should be introduced.
REFERENCES (55)
1.
Kucharz EJ, Korzeniewska-Koseła M, Kotulska A. Zalecenia postępowania w zapobieganiu i leczeniu gruźlicy u chorych leczonych antagonistami TNF-. Reumatologia 2008; 46: 51-54.  .
Google Scholar
 
 
2.
World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.  .
Google Scholar
 
 
3.
Gordon S, Mwandumba H. Respiratory tuberculosis. In: Clinical tuberculosis. Davies PDO, Barnes PF, Gordon SB (ed.). Fourth edition. Hodder Arnold, London 2008; 145-162.  .
Google Scholar
 
 
4.
Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United states and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-1366.  .
Google Scholar
 
 
5.
Gruźlica i choroby układu oddechowego w Polsce w 2008 r. Korzeniewska-Koseła M (red.). Instytut Gruźlicy i Chorób Płuc, Warszawa 2009.  .
Google Scholar
 
 
6.
Lewandowska K. Częstość występowania utajonego zakażenia Mycobacterium tuberculosis określana przy pomocy odczynu tuberkulinowego i testu wydzielania interferonu- -gamma w próbie populacji ogólnej i osadzonych w zakładach karnych województwa mazowieckiego. 2009. Praca doktorska (przygotowana do obrony).  .
Google Scholar
 
 
7.
Gołąb J, Jakóbisiak M. Cytokiny. W: Immunologia. Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T. (red.). Wydawnictwo Naukowe PWN, Warszawa 2008; 108-152.  .
Google Scholar
 
 
8.
Wallis RS. Tumor necrosis factor antagonists: structure, function and tuberculosis risks. Lancet Infect Dis 2008; 8: 601-611.  .
Google Scholar
 
 
9.
Lin J, Ziring D, Desai S. TNF- blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126: 13-30. .
Google Scholar
 
 
10.
Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2008, Dec 29 (Epub ahead of print). .
Google Scholar
 
 
11.
Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-217. .
Google Scholar
 
 
12.
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor- neutralizing agent. N Engl J Med 2001; 345: 1098-1104. .
Google Scholar
 
 
13.
Skvara H, Duschek N, Karlhofer F. de novo tuberculosis during infliximab therapy in a patent with Behçet disease. J Dtsch Dermatol Ges 2009; 7: 616-619. .
Google Scholar
 
 
14.
Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009; 22: 403-409. .
Google Scholar
 
 
15.
Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379. .
Google Scholar
 
 
16.
Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265. .
Google Scholar
 
 
17.
Gómez-Reino JJ, Carmona L, Descalzo MÁ, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761. .
Google Scholar
 
 
18.
Screening for tuberculosis before TNF- antagonist initiation: Are current methods good enough? Joint Bone Spine 2008; 75: 112-115. .
Google Scholar
 
 
19.
Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune response to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973. .
Google Scholar
 
 
20.
Villiger PM, Zellweger JP, Möller B. Novel screening tools for latent tuberculosis: time to leave an old friend? Curr Opin Rheumatol 2009; 21: 238-243. .
Google Scholar
 
 
21.
Berkel GM, Cobelens FG, de Vries G, et al. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis 2005; 9: 310-316. .
Google Scholar
 
 
22.
Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-α antibody therapy. Am J Med 2006; 119: 639-646. .
Google Scholar
 
 
23.
Greenberg JD, Reddy SM, Schloss SG, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed- type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: A pilot study in rheumatoid arthritis. J Rheumatol 2008; 35: 770-775. .
Google Scholar
 
 
24.
Zabana Y, Domenech E, San Roman AL, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008; 14: 1387-1391. .
Google Scholar
 
 
25.
Tissot F, Zanetti G, Francioli P, et al. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-217. .
Google Scholar
 
 
26.
Aydin M, Cagatay T, Sunmez S, et al. Follow up results of patients receiving anti tumor necrosis factor antagonists and evaluation of risk of tuberculosis. Eur Respir J 2009; (Suppl. 53) 34: 455. .
Google Scholar
 
 
27.
Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Clin Rheumatol 2002; 16: 707-722. .
Google Scholar
 
 
28.
Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-313. .
Google Scholar
 
 
29.
Pai M. Guidelines on IGRAs: concordant or discordant. 2nd Global Symposium on IGRAs. May 30-June 1, 2009, Dubrovnik, Croatia. Wykład dostępny na stronie internetowej http://www.igrasymposium.com/i....
Google Scholar
 
 
30.
Pai M, O’Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Sem Respir Crit Care Med 2008; 29: 560-568. .
Google Scholar
 
 
31.
Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell- based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-34. .
Google Scholar
 
 
32.
Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and TST are both useful for latent TB screening in autoimmune diseases. Eur Respir J 2009; 33: 586-593. .
Google Scholar
 
 
33.
Lalvani A, Thillai M. Diagnosis of tuberculosis: principles and practice of using interferon-gamma release assays (IGRAs). Breathe 2009; 5: 303-309. .
Google Scholar
 
 
34.
Diel R, Hauer B, Loddenkemper R, et al. Empfelungen fûr das Tuberkulosescreening vor Gabe von TNF-αlpha-inhibitoren bei rheumatischen Erkrankungen. Pneumonologie 2009; 63: 329-334. .
Google Scholar
 
 
35.
Beglinger Ch, Dudler J, Mottet Ch, et al. Screening for tuberculosis infection before initiation of anti-TNF-αlpha therapy. Swiss Med Wkly 2007; 137: 621-622. .
Google Scholar
 
 
36.
Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antygen-specific interferon-gamma assay. Ann Rheum Dis 2008; 67: 84-90. .
Google Scholar
 
 
37.
Martin J, Walsh C, Gibbs A, et al. Comparison of interferon-­ -gamma-release assays and conventional screening tests before tumor necrosis factor-alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010; 69: 181-185. .
Google Scholar
 
 
38.
Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-αlpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-913. .
Google Scholar
 
 
39.
Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008; 35: 1271-1276. .
Google Scholar
 
 
40.
Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800. .
Google Scholar
 
 
41.
Efthimiou P, Sood S. Quantiferon TB gold test: The new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 2007; 66: 276. .
Google Scholar
 
 
42.
Raval A, Akhavan-Toyserkani G, Brinker A, et al. Characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007; 147: 699-702. .
Google Scholar
 
 
43.
Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-806. .
Google Scholar
 
 
44.
Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Attenuated response to purified protein derivate in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361. .
Google Scholar
 
 
45.
Sellam J, Hamdi H, Roy C, et al. Comparison of in vitro- specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-1615. .
Google Scholar
 
 
46.
Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2799-2806. .
Google Scholar
 
 
47.
Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132. .
Google Scholar
 
 
48.
Theis VS, Rhodes JM. Minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 19-30. .
Google Scholar
 
 
49.
Carmona L, Gömez-Reino JJ, Rodriguez-Valverde V, et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772. .
Google Scholar
 
 
50.
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-αlpha treatment. Thorax 2005; 60: 800- 805. .
Google Scholar
 
 
51.
Sterling TR. New approaches to the treatment of latent tuberculosis. Sem Respir Crit Care Med 2008; 29: 532-541. .
Google Scholar
 
 
52.
Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lun Dis 2008; 12: 1352-1364. .
Google Scholar
 
 
53.
Den Broeder AA, Vonkeman H, Creemers MCW, et al. Characteristics of tuberculosis during anti-TNF treatment in RA patients in the Netherlands and influence of pre-treatment screening and treatment. Ann Rheum Dis 2005; 64 (Suppl III): 82. .
Google Scholar
 
 
54.
Escalante P. In the clinic. Tuberculosis. Ann Intern Med 2009; 150, ITC 6.1- 6.14. .
Google Scholar
 
 
55.
Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the BSR Biologics Register (BSRBR). EULAR 2008 (THUO134). Ann Rheum Dis 2008; 67 (Suppl II): 178.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
Send by email
RELATED ARTICLE
The spleen as a starting point to the final diagnosis – an atypical presentation of tuberculosis during anti-tumor necrosis factor therapy
Original paper
Recommendations for prophylaxis and management of tuberculosis in patients treated with TNF-α antagonists
Tuberculosis in a patient with rheumatoid arthritis treated with infliximab
Lung tuberculosis in a patient suffering from granulomatosis with polyangiitis (Wegener's granulomatosis) and receiving immunosuppressive treatment
Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy
Indexes
 
Keywords index
Topics index
Authors index
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top